Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized...

Area of Science:

• Ophthalmology
• Diabetic Retinopathy Treatment
• Clinical Trials

Background:

• Panretinal photocoagulation (PRP) is standard for proliferative diabetic retinopathy but can cause vision loss and diabetic macular edema (DME).
• Evaluating ranibizumab as a less invasive alternative to PRP is crucial for patient outcomes.

Purpose of the Study:

• To assess if intravitreous ranibizumab is noninferior to PRP in maintaining visual acuity for proliferative diabetic retinopathy patients.
• To compare secondary outcomes including visual field loss and DME development between the two treatments.

Main Methods:

• A randomized clinical trial involving 305 adults with proliferative diabetic retinopathy across 55 US sites.
• Participants were assigned to either PRP or intravitreous ranibizumab injections, with ranibizumab also used for DME in both groups.
• The primary outcome was mean visual acuity change at 2 years, with secondary outcomes assessing visual field, vitrectomy rates, DME, and neovascularization.

Main Results:

• Ranibizumab showed noninferior visual acuity compared to PRP (+2.8 vs +0.2 letter improvement; P < .001 for noninferiority).
• PRP treatment resulted in significantly greater peripheral visual field loss, more frequent vitrectomies, and higher rates of DME development.
• No significant difference was observed in retinal neovascularization between the groups; cardiovascular events were similar.

Conclusions:

• Intravitreous ranibizumab is a noninferior treatment to PRP for visual acuity in proliferative diabetic retinopathy at two years.
• Ranibizumab may offer a favorable alternative to PRP, potentially with fewer adverse effects on visual fields and DME.
• Longer-term studies are warranted, but ranibizumab presents a promising treatment option for this patient population.